Chris Ryan

Gilead will voluntarily withdraw the United States indication for sacituzumab govitecan in metastatic urothelial cancer.

Belzupacap sarotalocan produced complete responses in patients with low-grade non–muscle-invasive bladder cancer.

Updated RAMP 201 data will support an NDA submission to the FDA for avutometinib plus defactinib in recurrent low-grade serous ovarian cancer.

The European Commission has granted orphan medicinal product designation to VCN-01 for the treatment of patients with retinoblastoma.

The FDA has granted rare pediatric disease designation to galinpepimut-S for acute myeloid leukemia.

The FDA has approved Optune Lua for concurrent use with PD-1/PD-L1 inhibitors or docetaxel in metastatic non–small cell lung cancer.

The FDA has granted orphan drug designation to IMM-1-104 for pancreatic cancer.

Toripalimab has been approved in India and China’s Hong Kong Special Administrative Region for recurrent or metastatic nasopharyngeal carcinoma.

The DetermaIO gene expression test was predictive of responses to neoadjuvant atezolizumab plus chemotherapy in early-stage triple-negative breast cancer.

The FDA approved inavolisib plus palbociclib/fulvestrant for select PIK3CA-mutated, HR-positive, HER2-negative, advanced breast cancer.

A Type II variation application has been submitted to the EMA for subcutaneous daratumumab plus VRd in newly diagnosed multiple myeloma.

The combination of talazoparib and enzalutamide improved overall survival in metastatic castration-resistant prostate cancer.

LBL-024 received breakthrough therapy designation in China for pretreated advanced extrapulmonary neuroendocrine carcinoma.

Apalutamide was associated with an improved 24-month overall survival rate vs enzalutamide in metastatic castration-sensitive prostate cancer.

The SunRISe-2 trial of TAR-200 plus cetrelimab in muscle-invasive bladder cancer not undergoing radical cystectomy is being discontinued.

HLX11—a pertuzumab biosimilar—plus trastuzumab/docetaxel met the pCR end point in a phase 3 trial in early or locally advanced HER2-positive breast cancer.

The FDA granted priority review to acalabrutinib for previously untreated mantle cell lymphoma.

MRD negativity was sustained at 1 year following the cessation of maintenance lenalidomide in multiple myeloma.

A sBLA has been submitted to the FDA for subcutaneous daratumumab plus VRd in ASCT-ineligible or -deferred multiple myeloma.

Cadonilimab plus chemotherapy has been approved in China for first-line locally advanced or metastatic gastric/GEJ adenocarcinoma.

Daratumumab plus VRd improved MRD-negativity rates in transplant-ineligible or -deferred, newly diagnosed multiple myeloma.

The FDA’s ODAC voted against the risk:benefit profile of PD-1 inhibitors in first-line advanced gastric/GEJ adenocarcinoma with a PD-L1 of less than 1.

The FDA approved osimertinib for EGFR-mutated, locally advanced, unresectable, non–small cell lung cancer after chemoradiation.

The European Commission has approved toripalimab in indications for nasopharyngeal carcinoma and esophageal squamous cell carcinoma.

LODER plus chemotherapy led to responses and improved overall survival in unresectable, locally advanced pancreatic cancer.

Enfortumab vedotin plus pembrolizumab has been approved in Japan for first-line radically unresectable urothelial carcinoma.

The WHO updated its cervical cancer prevention guidelines to include CINtec PLUS Cytology, a dual-stain cytology test.

The CHMP has recommended the European approval of serplulimab for the first-line treatment of extensive-stage small cell lung cancer.

The CAR T-cell therapy GCC19CART was safe and showed clinical activity in relapsed/refractory metastatic colorectal cancer.

The FDA has approved isatuximab plus bortezomib, lenalidomide, and dexamethasone for newly diagnosed, transplant-ineligible myeloma.